The American Urological Association 2016 Annual Meeting
The annual meeting of the American Urological Association (AUA) was held from May 6 to 10 in San Diego and attracted more than 12,000 participants from around the world, including clinicians, academicians, allied health professionals, and others interested in urology. The conference highlighted recent advances in the prevention, detection, and treatment of urologic conditions, with presentations focusing on the advancement of urologic patient care.
In one study, Andrew Cohen, M.D., of the University of Chicago, and colleagues evaluated whether statin use decreased the risk of future nephrolithiasis and explored the relationship between serum lipid values and risk of future stone development. For the study, 101,259 patients diagnosed with hyperlipidemia from 2009 to 2011 and prescribed a statin were identified and followed until new stone diagnosis (until June 2015).
“For patients with a history of stones (1,785) there was a 36 percent reduction in the incidence of recurrent stones for those patients on any statin medication,” Cohen said. “On multivariable analysis, statin use was associated with significant 43 and 47 percent decreased odds of new stones among stone-naive patients and recurrent stone formers, respectively, compared with no statin use, after adjusting for race, body mass index, gender, and other comorbidities.”
The investigators found that low-density lipoprotein or total cholesterol did not correlate with stone risk; however, elevated triglycerides were a risk factor for increased incidence of kidney stones.
“Statins may be protective against stone formation. The association between a decreased incidence of nephrolithiasis and statins is strongest for those patients with a history of stones,” Cohen said. “The mechanism of action may be due to anti-inflammatory and antioxidant properties rather than direct lipid lowering effects.”
In another study, Daniel Lin, M.D., from the University of Washington Medical Center in Seattle, and colleagues found that African-American men and men with higher risk pathology may benefit from chemotherapy after radical prostatectomy. The investigators randomized patients at a high risk for relapse after prostatectomy to either observation or a chemotherapy regimen involving docetaxel and prednisone administered every three weeks for 18 weeks.
The investigators observed a benefit in progression-free survival among African-American men and men with higher risk pathology, despite a lack of a statistically significant improvement in progression-free survival for the study group as a whole. The most common adverse events included neutropenia, followed by hyperglycemia, fatigue, and febrile neutropenia.
“What this study shows is that men with aggressive disease, thus at higher risk for prostate cancer relapse, may benefit the most from chemotherapy after radical prostatectomy,” Sam S. Chang, M.D., an AUA spokesperson, said in a statement. “As urologists, we are always looking for new treatment options for our patients following localized therapy. Despite our best efforts, our established treatments for localized prostate cancer fail 30 percent of the time. Knowing to whom we should offer adjuvant chemotherapy is a real step forward in our attempts to improve our therapy success.”
Mohit Khera, M.D., of the Baylor College of Medicine in Houston, and colleagues found that LPCN 1021, an orally administered testosterone undecanoate therapy, was safe and effective for the treatment of patients with hypogonadism. The investigators randomized 315 men with hypogonadism to LPCN 1021 (210 patients) or testosterone gel (active control; 105 patients). The investigators found that the drug was well tolerated and had a favorable adverse event profile in long-term management. Specifically, the investigators found no hepatic safety concerns, and gastrointestinal adverse effects were in line with active control.
“Based on the results of this study, we might be closer than ever to having an oral form of therapy to treat the millions of men with hypogonadism,” Tobias S. Köhler, M.D., M.P.H., an AUA spokesperson and associate professor of surgery at the Southern Illinois University School of Medicine in Springfield, said in a statement. “Making sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we’ve found so far has shown we’re on the right track.”
AUA: BRCA Mutations May Play Role in Prostate Cancer
TUESDAY, May 10, 2016 (HealthDay News) — A man’s risk of aggressive and fatal prostate cancer may be heavily influenced by gene mutations previously linked to breast and ovarian cancer in women, a trio of new studies suggests. Findings from the studies were presented at the annual meeting of the American Urological Association, held from May 6 to 10 in San Diego.
AUA: Nasal Spray Linked to Decreased Nocturia, Better QoL
MONDAY, May 9, 2016 (HealthDay News) — A nasal spray may provide relief for patients struggling with nocturia, while other research highlights the positive benefits of exercise on the condition. Both studies were presented at the annual meeting of the American Urological Association, held from May 6 to 10 in San Diego.
Copyright © 2016 HealthDay. All rights reserved.
